King Charles III Makes World Debut as Tour Starts in Germany

Britain's King Charles and Queen Camilla leave after their visit to the Bolton Town Hall, in Bolton, Britain January 20, 2023. (Reuters)
Britain's King Charles and Queen Camilla leave after their visit to the Bolton Town Hall, in Bolton, Britain January 20, 2023. (Reuters)
TT

King Charles III Makes World Debut as Tour Starts in Germany

Britain's King Charles and Queen Camilla leave after their visit to the Bolton Town Hall, in Bolton, Britain January 20, 2023. (Reuters)
Britain's King Charles and Queen Camilla leave after their visit to the Bolton Town Hall, in Bolton, Britain January 20, 2023. (Reuters)

Britain’s new king will make his debut on the world stage Wednesday, three days later and 550 miles (885 kilometers) northeast of where he had intended.

Although King Charles III will be greeted with a hearty “willkommen” in Berlin rather than “bienvenue” in Paris, his goals remain the same: to cement Britain’s improving relations with Europe and show that he can help the UK win hearts and minds abroad just as his mother did so successfully for seven decades.

But the decision to cancel the first leg of his trip due to protests over planned pension changes in France may make it harder for Charles to make his mark during his first big international mission as monarch. And first impressions matter as Charles, 74, prepares for his coronation on May 6.

“Charles will have fewer opportunities to present himself,” said Arianne Chernock, a royal expert and professor of modern British history at Boston University. “This means that he’ll need to be very disciplined about using those opportunities available to maximize his impact — there won’t be many second chances on this trip.”

Charles, who ascended the throne after the death of Queen Elizabeth II in September, had something bigger in mind when this coming out party as king was announced.

Billed as a multi-day tour of the European Union’s two biggest countries, the trip was designed to underscore British Prime Minister Rishi Sunak’s efforts to rebuild relations with the bloc after six years of arguments over Brexit and highlight the countries’ shared history as they work together to combat Russian aggression in Ukraine.

Now everything rests on Germany.

The truncated trip starts Wednesday in Berlin, where German President Frank-Walter Steinmeier will welcome Charles and Camilla, the queen consort, at the historic Brandenburg Gate.

The king is scheduled to give a speech to the Bundestag, Germany’s parliament, on Thursday. He will also meet Chancellor Olaf Scholz, talk to Ukrainian refugees and meet with British and Germany military personnel who are working together on joint projects.

The royal couple go to Hamburg on Friday, where they will visit the Kindertransport memorial for Jewish children who fled from Germany to Britain during the Third Reich, and attend a green energy event before returning to the UK.

The king was urged to make the trip by Sunak, who during his first six months in office negotiated a settlement to the long-running dispute over post-Brexit trading rules for Northern Ireland and reached a deal with France to combat the people smugglers ferrying migrants across the English Channel in small boats.

Sunak hopes goodwill created by a royal visit can help pave the way for progress on other issues, including Britain’s return to an EU program that funds scientific research across Europe.

This is the first big test of whether Charles can be an effective conduit for the “soft power” the House of Windsor has traditionally wielded, helping Britain pursue its geopolitical goals through the glitz and glamor of a 1,000-year-old monarchy.

The Windsors are among the most recognizable people on the planet. While their formal powers are strictly limited by law and tradition, they draw attention from the media and the public partly because of the historic ceremonies and regalia that accompany them — and also because the public is fascinated by their personal lives.

The late Queen Elizabeth II was the embodiment of this — the monarch everyone wanted to meet for tea, if for no other reason than that she’d been around so long.

Elizabeth’s influence stemmed in part from the fact that she made more than 100 state visits during her 70 years on the throne, meeting presidents and prime ministers around the world in a reign that lasted from the Cold War to the information age.

But questions remain about whether Charles has the same star power as his mother, dubbed “Queen of the World” by one biographer, Robert Hardman.

Charles has fewer years to make his mark and will not try to copy her, said Bronwen Maddox, who heads the Chatham House public affairs think tank in London.

“He’s getting this (opportunity) towards the end of his life, and it’s very much a chance to make the best of it without claiming that it is the same, in any way, as his mother,” she said. “I think he will find his own way to do it.”

Charles, a former naval officer who is the first British monarch to earn a university degree, is expected to insert heft where his glamorous mother once wielded star power.

As Britain’s head of state, the king meets weekly with the prime minister and retains his mother’s role as leader of the Commonwealth.

His visit to Germany will showcase these roles while also giving him an opportunity to highlight the causes he holds dear, like sustainability and the environment.

But there will also be a full dose of the pomp and circumstance that screams royal visit, starting with a ceremonial welcome at the Brandenburg Gate, the neoclassical landmark in the center of Berlin that has provided the backdrop to so much of German history. White tie and tiaras are expected to be on display during a state dinner at Schloss Bellevue, the German president’s official residence.

There will be plenty, therefore, to attract the crowds in Germany and demonstrate to people back home that Charles has eased into the role of monarch and chief diplomat.

“In some ways, Charles does not have to do very much for people to follow him because there’s the mystique of the institution,” Chernock said. “I think people are fascinated by his family and all of the drama surrounding it. So he could stand perfectly still and not utter a word and he would still draw crowds.”



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”